Form 4: Hoth Therapeutics CEO Acquires 800K Shares, Sells 310K for Tax

Hoth Therapeutics CEO Robb Knie acquired 800,000 shares of common stock and disposed of 310,744 shares for tax purposes.

Summary

• Robb Knie, CEO and President of Hoth Therapeutics, Inc., acquired 800,000 shares of common stock on August 27, 2025.
• These shares were restricted stock issued under the company's Amended and Restated 2022 Equity Incentive Plan and vested immediately upon grant.
• On August 28, 2025, Knie disposed of 310,744 shares of common stock at a price of $1.21 per share.
• This disposition was for the payment of tax liability by withholding securities.
• Following these transactions, Knie directly beneficially owns 547,387 shares of Hoth Therapeutics common stock.

Sentiment

Score: 7

Explanation: The CEO received a substantial equity grant, aligning interests with shareholders, with a portion sold to cover tax obligations, which is a standard practice.

Positives

• CEO Robb Knie received a significant grant of 800,000 restricted shares, indicating continued alignment of management interests with shareholders.
• The immediate vesting of the restricted stock grant suggests confidence in the CEO's ongoing contribution and performance.

Negatives

• The disposition of 310,744 shares, while for tax purposes, reduces the CEO's direct beneficial ownership from the peak after the grant.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing.

Industry Context

This filing is a routine insider transaction report and does not provide specific industry context or trends.

Related Party Transactions

• Robb Knie, CEO and President, received 800,000 shares of restricted stock under the Issuer's Amended and Restated 2022 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders due to the significant stock grant.
• Employees: The equity incentive plan benefits executives, potentially motivating performance.

Key Dates

Recommendation

The filing details a routine executive compensation event (stock grant) and a subsequent tax-related sale. While the grant aligns management with shareholder interests, the sale is a standard practice and does not signal a change in the company's fundamental outlook or warrant a change in investment thesis based solely on this Form 4.

Keywords

Hoth Therapeutics, HOTH, Robb Knie, Insider Trading, Stock Grant, Equity Incentive Plan, CEO Stock, SEC Form 4, Restricted Stock